finance.yahoo.com Earnings
Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?
Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook to US$3.88 billion–US$3.93 billion. Alongside these results, BioMarin filed a US$719.24 million common stock shelf registration for an ESOP-related offering, highlighting how management is …